| Autor: |
Uss AL; Byelorussian Center For Bone Marrow Transplantation, Minsk., Zmachinskiĭ VA, Milanovich NF, Skriagin AE, Dziuba EV, Vlasenkova SV, Solov'eva NS, Batan ZE, Mitskevich PB, Zavgorodniaia IL, Aleĭnikova OV, Zhavrid EA |
| Jazyk: |
ruština |
| Zdroj: |
Voprosy onkologii [Vopr Onkol] 2000; Vol. 46 (5), pp. 619-23. |
| Abstrakt: |
In 1995-1999, 67 patients with relapsed Hodgkin's disease or refractory to chemotherapy (group A--first relapse, B--primary refractory disease, and C--repeated relapse) received cytoreductive (dexaBEAM, DHAP) therapy followed by high-dose BEAM chemotherapy and autologous bone marrow or blood cell transplantation. Early postoperative transplant-related mortality rate was 4.5%. At day 100, complete remission rates were: group A--95.6%; B--74.1%; and C--76.5%. Survival for all patients was: overall--61.9%; event-free--43.9%; disease-free--46%; and relapse-free survival--49.5%. Such factors as primary refractory disease, age over 30 years and response to cytoreductive therapy had significant influence on overall survival prognosis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
